

HONORABLE JUDGE THOMAS S. ZILLY

**IN THE UNITED STATES DISTRICT COURT  
FOR THE WESTERN DISTRICT OF WASHINGTON  
AT SEATTLE**

L.B. and M.B., on behalf of their minor  
child A.B., and on behalf of similarly  
situated others; L.B.; M.B., C.M. and  
A.H., on behalf of their minor child  
J.M., and on behalf of similarly situated  
others; C.M.; and A.H.,

Plaintiffs,

vs.

PREMERA BLUE CROSS,

Defendant.

Case No. 2:23-cv-00953-TSZ

**DEFENDANT PREMERA BLUE CROSS’  
BRIEF ADDRESSING *SKRMETTI***

Pursuant to the Court’s direction (Dkt. 176), Defendant Premera Blue Cross (“Premera”) respectfully submits this brief addressing the effect of *United States v. Skrmetti*, 145 S. Ct. 1816 (2025), on this Court’s April 18, 2025 order granting Plaintiffs partial summary judgment on their sex discrimination claim (Dkt. 169, “the Order”). In *Skrmetti*, the Supreme Court upheld a state law that prohibited certain medical treatments for minors for purposes of treating gender dysphoria. Likewise, Premera’s medical policy challenged in this lawsuit denies coverage for surgery for minors when sought to treat a diagnosis of gender dysphoria.

The Supreme Court’s decision in *Skrmetti* is dispositive. The Order held that “Premera’s medical policy facially discriminates on the basis of sex.” Dkt. 169 at 16; *see also id.* at 19 (“Premera’s policy is ‘textbook sex discrimination.’”). *Skrmetti* squarely disagrees with this conclusion. *See* 145 S. Ct. at 1830 (“SB1 clearly does not classify on the basis of sex”). The Order

1 also held that “Premera’s medical policy discriminates on the basis of sex by overtly  
 2 differentiating between transgender and cisgender youth or by using the proxy of gender  
 3 dysphoria.” Dkt. 169 at 20. *Skrmetti* squarely disagrees with this conclusion, too. *See* 145 S. Ct. at  
 4 1833 (“SB1 does not exclude any individual from medical treatments on the basis of transgender  
 5 status”). Rejecting the reasoning adopted by the Order, *Skrmetti* confirms that a classification based  
 6 on a medical diagnosis of gender dysphoria is not sex-based discrimination and thus does not violate  
 7 the Constitution or (directly relevant here) federal laws, such as Section 1557, that prohibit  
 8 discrimination on the basis of sex. At the very least, Premera could not have had “adequate notice,  
 9 when [it] accepted federal funding,” that benefits determinations based on a gender-dysphoria  
 10 diagnosis would constitute discrimination on the basis of sex. *Roe v. Critchfield*, 131 F.4th 975, 992  
 11 (9th Cir. 2025). The Order’s holding of sex discrimination, therefore, cannot stand under *Skrmetti*,  
 12 as explained below.

13 This Court should vacate its grant of partial summary judgment to Plaintiffs on the basis of  
 14 sex discrimination and enter judgment for Premera on that claim.

### 15 ARGUMENT

16 *Skrmetti* upheld a Tennessee law, SB1, which prohibits hormones, puberty blockers, and  
 17 surgery, but only when provided “for the purpose of (1) ‘enabling a minor to identify with, or  
 18 live as, a purported identity inconsistent with the minor’s sex,’ or (2) ‘treating purported  
 19 discomfort or distress from a discordance between the minor’s sex and asserted identity.’”  
 20 *Skrmetti*, 145 S. Ct. at 1826 (cleaned up). The challengers to SB1 contended this “creates facial  
 21 sex-based classifications by defining the prohibited medical care based on the patient’s sex.” *Id.*  
 22 at 1829. They argued both that “SB1 classifies on the basis of sex because its prohibitions  
 23 reference sex” and that “SB1 works a sex-based classification because application of the law  
 24 turns on sex.” *Id.*

25 The Supreme Court disagreed. It determined that SB1 “clearly does not classify on the  
 26 basis of sex.” *Id.* at 1830. “Rather, SB1 prohibits healthcare providers from administering  
 27 puberty blockers and hormones to *minors* for certain *medical uses*, regardless of a minor’s sex.”

1 *Id.* at 1829 (emphasis in the original). The Court elaborated further: “Under SB1, a healthcare  
 2 provider may administer puberty blockers or hormones to any minor to treat a congenital defect,  
 3 precocious puberty, disease, or physical injury; a healthcare provider may not administer puberty  
 4 blockers or hormones to any minor to treat gender dysphoria, gender identity disorder, or gender  
 5 incongruence. *The application of that prohibition does not turn on sex.*” *Id.* at 1830-31  
 6 (emphasis added) (citations omitted).

7 *Skrmetti* controls here because this case likewise involves an age limit on gender-  
 8 affirming procedures that fully turns on medical diagnosis, medical condition, and medical  
 9 treatment. Premera’s medical policy for gender-affirming surgery provides coverage for chest  
 10 surgery for males and females alike, except for individuals under 18 who have “a diagnosis of  
 11 gender dysphoria.” Dkt. 169 at 6-7. As Plaintiffs acknowledged in their partial summary  
 12 judgment motion, “Premera covers mastectomies for cancer, excess breast tissue and other  
 13 conditions for minors,” but “minors are categorically excluded from gender-affirming chest  
 14 surgery” (that is, chest surgery to address a diagnosis of gender dysphoria). Dkt. 44 at 1-2.  
 15 Premera’s medical policy, therefore, is *precisely* analogous to the law in *Skrmetti*, where the  
 16 Court found there was no sex discrimination: “Under SB1, a healthcare provider may administer  
 17 puberty blockers or hormones to any minor to treat a congenital defect, precocious puberty,  
 18 disease, or physical injury; a healthcare provider may not administer puberty blockers or  
 19 hormones to any minor to treat gender dysphoria, gender identity disorder, or gender  
 20 incongruence.” *Skrmetti*, 145 S. Ct. at 1830-31 (citations omitted). In short, as in *Skrmetti*,  
 21 Premera’s medical policy denies coverage for surgery “to *minors* for certain *medical uses*,  
 22 regardless of a minor’s sex.” *Id.* at 1830 (emphasis in the original).

23 *Skrmetti* therefore confirms that Premera does not “discriminate on the basis of sex” when  
 24 it imposes an age limitation for chest surgery as a treatment for gender dysphoria. Indeed,  
 25 *Skrmetti* forecloses the Order’s Section 1557 holding.

26 First, *Skrmetti* rejected the notion that a “mere reference to sex,” whether in the law or in  
 27 a medical policy, means that the prohibition is “sex-based.” 145 S. Ct. at 1829. Quoting the

Fourth Circuit’s decision in *Kadel v. Folwell*, 100 F.4th 122 (4th Cir. 2024), *vacated*, No. 24-99, 2025 WL 1787687 (U.S. June 30, 2025), the Order in this case relied on the fact that, under the medical policy, “some patients will be eliminated from candidacy for these surgeries solely from knowing their sex assigned at birth.” Dkt. 169 at 17 (quoting *Kadel*, 100 F.4th at 153). The Order further explained that, under the medical policy, the coverage decision can be different “depending on whether [the minor’s] natal sex is male or female.” *Id.* at 18. *Skrmetti* firmly rejected that logic, explaining that kind of reductive approach is “especially inappropriate in the medical context,” where “[s]ome medical treatments and procedures are uniquely bound up in sex.” *Skrmetti*, 145 S. Ct. at 1829.

Second, *Skrmetti* rejected the Order’s holding that “gender dysphoria is a proxy for transgender status.”<sup>1</sup> Dkt. 169 at 20. *Skrmetti* held that a proxy-discrimination claim could not be sustained because “there is a ‘lack of identity’ between transgender status and the excluded medical diagnoses.” *Skrmetti*, 145 S. Ct. at 1833. In *Skrmetti*, the exclusion of puberty blockers and hormone treatments for gender dysphoria did not discriminate against transgender people because “both transgender and nontransgender individuals” are able to seek those treatments for other conditions. *Id.* *Skrmetti* relied on *Geduldig v. Aiello*, 417 U.S. 484 (1974), explaining that, like the pregnancy coverage exclusion in *Geduldig*, “SB1 does not exclude any individual from medical treatments on the basis of transgender status but rather removes one set of diagnoses—gender dysphoria, gender identity, and gender incongruence—from the range of treatable conditions.” *Skrmetti*, 145 S. Ct. at 1833. Similarly, here, an age limitation for surgery for gender dysphoria does not discriminate against transgender people because “both transgender and nontransgender individuals” are able to seek surgery for other conditions. *Id.*

Under *Geduldig* and *Skrmetti*, Plaintiffs would need to show that Premera’s medical

---

<sup>1</sup> The Order also concluded that “gender identity is a protected characteristic.” Dkt. 169 at 19. The Court in *Skrmetti* rejected the plaintiffs’ sex discrimination argument without addressing that question “because SB1 does not classify on the basis of transgender status.” 145 S. Ct. at 1832-33. Neither does Premera’s medical policy, for the same reasons.

1 policy is “mere pretext for invidious sex discrimination.” *Id.* The *Skrmetti* challengers did not  
 2 attempt to make such a showing, *id.*, and the Order here does not hold that the medical policy  
 3 was motivated by invidious sex discrimination. No such claim would be factually plausible in  
 4 this case.<sup>2</sup>

5 Third, the Order relied extensively on the Fourth Circuit’s decision in *Kadel*, declining to  
 6 engage at all with the contrary reasoning in the 6th Circuit’s decision in *Skrmetti*. Dkt. 169 at  
 7 15, 17-20. But the 6th Circuit’s decision was affirmed, and the Supreme Court has vacated *Kadel*  
 8 in light of *Skrmetti*. See *Folwell v. Kadel*, No. 24-99, 2025 WL 1787687 (U.S. June 30, 2025).  
 9 Without *Kadel* (and the two district-court cases adopting a similar rationale), the Order rests on  
 10 no authority.

11 Fourth, *Skrmetti* rejects the Order’s reliance on *Bostock v. Clayton County*, 590 U.S. 644  
 12 (2020), see Dkt. 169 at 15-16, 20, and in so doing confirms that *Skrmetti*’s logic applies beyond  
 13 equal protection jurisprudence to civil-rights statutes such as Section 1557. 145 S. Ct. at 1834;  
 14 see *Doe v. Snyder*, 28 F.4th 103, 114 (9th Cir. 2022).

15 Specifically, *Skrmetti* held that, even under its analysis in *Bostock*, a Title VII case, limits  
 16 on medical treatments for gender dysphoria are not sex discrimination. “[N]either [the patient’s]  
 17 sex nor his transgender status is the but-for cause of his inability to obtain” the treatment; medical  
 18 diagnosis is. 145 S. Ct. at 1834. *Skrmetti* thus confirms that cases like *Kadel* erred in reading

---

19 <sup>2</sup> Plaintiffs can show pretext “in two ways”: (1) indirectly, by showing that [Premera’s] proffered  
 20 explanation is ‘unworthy of credence’ because it is internally inconsistent or otherwise not  
 21 believable, or (2) directly, by showing that unlawful discrimination more likely motivated  
 22 [Premera].” *Lindsey v. SLT Los Angeles, LLC*, 447 F.3d 1138, 1148 (9th Cir. 2006). Plaintiffs’  
 23 perfunctory discussion of pretext in their summary judgment motion does not create a factual  
 24 dispute under either method. Since *Skrmetti* approved the same restrictions, Premera’s policy is  
 25 certainly not “unworthy of credence.” And Plaintiffs have presented no direct evidence of  
 26 discriminatory animus. “[D]irect evidence of discrimination is that which, ‘if believed, proves  
 27 the fact [of discriminatory animus] without inference or presumption.’” *Hittle v. City of Stockton*,  
 101 F.4th 1000, 1012-13 (9th Cir. 2024) (second brackets in the original). “Direct evidence  
 typically consists of clearly sexist, racist, or similarly discriminatory statements or actions....”  
*Coghlan v. Am. Seafoods Co. LLC*, 413 F.3d 1090, 1095 (9th Cir. 2005). Plaintiffs offered no  
 such evidence, only impermissible speculation. See *Korkosz v. Clark Cnty.*, 379 F. App’x 593,  
 596 (9th Cir. 2010).

1 *Bostock* to render unlawful the enforcement of reasonable age limitations for gender-affirming  
 2 care. As in *Skrmetti*, Premera’s challenged coverage determinations turn on medical diagnosis,  
 3 and specifically “a diagnosis of gender dysphoria.” Dkt. 169 at 7. And under *Skrmetti*, “[t]he  
 4 application of that prohibition does not turn on sex.” 145 S. Ct. at 1831.

5 The Order also relied on *Kadel*’s conclusion that a prohibition on coverage for gender-  
 6 affirming care “stems from gender stereotypes about how men or women should present.” Dkt.  
 7 169 at 17 (quoting *Kadel*, 100 F.4th at 153). But *Skrmetti* specifically rejected the argument that  
 8 “SB1 enforces a government preference that people conform to expectations about their sex.”  
 9 145 S. Ct. at 1832. The Court expressly concluded that “the plaintiffs’ allegations of sex  
 10 stereotyping are misplaced.”<sup>3</sup> *Id.*

11 Finally, the Order declined to stay this case pending *Skrmetti*. See Dkt 169 at 19 n.8. The  
 12 Order suggested that, because *Skrmetti* does not “involve any claim under ACA § 1557,” it was  
 13 “unlikely to provide guidance” in this case. *Id.* Specifically, the Order noted that, because this  
 14 is not a constitutional case, it “need not decide what level of scrutiny applies with respect to  
 15 distinctions made on the basis of gender identity and/or transgender status.” *Id.* In *Skrmetti*,  
 16 however, the Supreme Court declined to address the level of scrutiny question. See 145 S. Ct. at  
 17 1832-33 (declining to address whether “transgender individuals are a suspect or quasi-suspect  
 18 class” because “SB1 does not classify on the basis of transgender status”). Instead, the Court  
 19 resolved the case based on its holding that “SB1 clearly does not classify on the basis of sex.”  
 20 *Id.* at \*9. While the Court made this holding while resolving a constitutional claim of sex  
 21 discrimination, § 1557 requires this Court to resolve the *exact same question* that was at issue in  
 22 *Skrmetti*: whether Premera’s medical policy discriminates “on the basis of sex.” See Title IX, 20

---

23 <sup>3</sup> The Order also discounted the reasons Premera adopted the medical policy: (1) “a minor’s  
 24 insufficient maturity ‘to make a truly informed, educated decision’ and ‘to understand all of the  
 25 ramifications of such transformation including its irreversibility,’” and (2) a dearth of “studies  
 26 supporting gender-affirming surgeries for adolescents.” Dkt. 169 at 7. *Skrmetti*, however, found  
 27 legitimate Tennessee’s similar concerns that “the prohibited medical treatments are experimental,  
 can lead to later regret, and are associated with harmful—and sometimes irreversible—risks.”  
 145 S. Ct. at 1832, 1825-26.

1 U.S.C. § 1681(a) (“No person in the United States shall, on the basis of sex, be excluded from  
 2 participation in, be denied the benefits of, or be subjected to discrimination”), *incorporated by*  
 3 ACA § 1557, 42 U.S.C. § 18116(a). There simply is no basis for declining to follow *Skrmetti*’s  
 4 answer to that question in the context of § 1557.

### 5 CONCLUSION

6 This Court should vacate the Order’s grant of partial summary judgment to Plaintiffs on  
 7 their sex discrimination claim, enter judgment for Premera on that claim, and then dismiss this  
 8 case with prejudice.

9 DATED this 7th day of July, 2025.

10 KILPATRICK TOWNSEND & STOCKTON LLP

11 By /s/ Gwendolyn C. Payton  
 12 Gwendolyn C. Payton, WSBA No. 26752  
 13 gpayton@ktslaw.com  
 14 1420 Fifth Ave., Suite 3700  
 15 Seattle, WA 98101  
 16 Telephone: (206) 626-7714  
 17 Facsimile: (206) 623-6793

18 *Counsel for Premera Blue Cross*

19 By /s/ Stephanie N. Bedard  
 20 Stephanie N. Bedard\* (*admitted pro hac*  
 21 *vice*)  
 22 sbedard@ktslaw.com  
 23 1100 Peachtree Street NE, Suite 2800  
 24 Atlanta, GA 30309  
 25 Telephone: (404) 541-6039  
 26 Facsimile: (404) 541-3153

27 *Counsel for Premera Blue Cross*



**CERTIFICATE OF SERVICE**

I certify that on the date indicated below I caused a copy of the foregoing document, DEFENDANT PREMIERA BLUE CROSS' BRIEF ADDRESSING *SKRMETTI* to be filed with the Clerk of the Court via the CM/ECF system. In accordance with their ECF registration agreement and the Court's rules, the Clerk of the Court will send e-mail notification of such filing to the following attorneys of record:

<b>Eleanor Hamburger</b> <b>Daniel S. Gross</b> SIRIANNI YOUTZ SPOONEMORE HAMBURGER 3101 WESTERN AVENUE STE 350 SEATTLE, WA 98121 206-223-0303 Fax: 206-223-0246 Email: ehamburger@sylaw.com dgross@sylaw.com	<input checked="" type="checkbox"/> by CM/ECF <input type="checkbox"/> by Electronic Mail <input type="checkbox"/> by Facsimile Transmission <input type="checkbox"/> by First Class Mail <input type="checkbox"/> by Hand Delivery <input type="checkbox"/> by Overnight Delivery
<b>Omar Gonzalez-Pagan</b> <b>Kell L Olson</b> <b>Nicholas Hite</b> <b>Sasha J Buchert</b> LAMBDA LEGAL DEFENSE AND EDUCATION FUND, INC 120 WALL STREET 19TH FLOOR NEW YORK, NY 10005 646-307-7406 Email: ogonzalez-pagan@lambdalegal.org kolson@lambdalegal.org nhite@lambdalegal.org sbuchert@lambdalegal.org	<input checked="" type="checkbox"/> by CM/ECF <input type="checkbox"/> by Electronic Mail <input type="checkbox"/> by Facsimile Transmission <input type="checkbox"/> by First Class Mail <input type="checkbox"/> by Hand Delivery <input type="checkbox"/> by Overnight Delivery

DATED this 7th day of July, 2025.

**Kilpatrick, Townsend & Stockton LLP**

By: /s/ Gwendolyn C. Payton  
Gwendolyn C. Payton, WSBA No. 26752

*Counsel for Premiera Blue Cross*